PUBLISHER: Acute Market Reports | PRODUCT CODE: 1476523
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1476523
Cholesterol Lowering Drugs Market - Growth, Future Prospects and Competitive Analysis, 2024 - 2032
The cholesterol-lowering drugs market is expected to grow at a CAGR of 3.3% during the forecast period of 2024 to 2032, driven by increasing awareness of cardiovascular health, advancements in PCSK9 inhibitors, and the growing prevalence of lifestyle-related diseases. Despite challenges in medication adherence, the market demonstrated resilience. Manufacturers operating in the cholesterol-lowering drugs market are augmenting their research endeavors to incorporate bempedoic acid into their product development strategies. As an illustration, Esperion, a pharmaceutical company based in the United States, declared the FDA's approval of new drug applications (NDAs) about bempedoic acid in May 2019. Increasing awareness regarding the detrimental effects of cholesterol is a significant factor propelling the expansion of the market for cholesterol-lowering medications. Organizations are consulting investigational studies to ascertain which medications are well-tolerated by patients and subsequently modify their products as necessary. Increasing their production capacities, companies in the market for cholesterol-lowering medications are preparing to manufacture Evolocumab, which is prescribed to high-risk patients. Additionally, they are capitalizing on prospects to produce Canakinumab, an efficacious antibody that induces a substantial reduction in cardiovascular incidents. To treat hypercholesterolemia, manufacturers are developing PCSK9 inhibitors with enhanced properties. They are emphasizing the use of secondary prevention statins to reduce patients' LDL-C. The positive results attributed to CPSK9 inhibitors are generating income for firms operating in the cholesterol-lowering pharmaceutical industry. Geographically, North America led in revenue, while the Asia-Pacific region showcased the highest growth potential.
Key Market Drivers
Increasing Global Awareness and Education on Cardiovascular Health
The global emphasis on cardiovascular health and the increasing awareness of the risks associated with high cholesterol levels served as a significant driver for the Cholesterol-lowering Drugs market in 2023. Statins and combination therapies, as evidenced by the widespread use of medications like atorvastatin and rosuvastatin, played a crucial role in managing cholesterol levels. The evidence lies in the growing public awareness campaigns, healthcare initiatives, and educational programs highlighting the importance of cholesterol management for overall cardiovascular well-being.
Advancements in PCSK9 Inhibitors
Advancements in the development and adoption of PCSK9 inhibitors represented a key driver for the Cholesterol-lowering Drugs market in 2023. Medications like evolocumab and alirocumab gained prominence for their ability to significantly lower LDL cholesterol levels. The evidence for this driver is reflected in the expanding clinical evidence supporting the efficacy of PCSK9 inhibitors and their inclusion in treatment guidelines. The increased utilization of these drugs is anticipated to continue, contributing to market growth during the forecast period from 2024 to 2032.
Growing Prevalence of Lifestyle-Related Diseases
The growing prevalence of lifestyle-related diseases, including hypercholesterolemia, coronary artery disease, and higher triglycerides, fueled the demand for various cholesterol-lowering drug classes in 2023. Bile Acid Sequestrants, Fibrates, and Cholesterol Absorption Inhibitors saw increased utilization. The evidence lies in the rising incidence of these diseases, driven by sedentary lifestyles, unhealthy dietary habits, and an aging population. As these conditions continue to grow, the demand for cholesterol-lowering medications is expected to persist.
Restraint
Despite the positive drivers, the Cholesterol-Lowering Drugs market faced a notable restraint in the form of Medication Adherence Challenges. The evidence for this restraint is apparent in the suboptimal adherence rates among patients prescribed cholesterol-lowering medications. Factors such as complex dosing regimens, side effects, and the long-term nature of cholesterol management contribute to poor adherence. Overcoming these challenges is essential to maximizing the effectiveness of cholesterol-lowering treatments.
Market Segmentation by Drug Class
The segmentation analysis based on drug classes showcased distinct trends in 2023. While Statins and Combination therapies led in revenue, PCSK9 Inhibitors exhibited the highest CAGR during the forecast period of 2024 to 2032. This indicates a balance between the established use of statins and the growing adoption of advanced therapies for specific patient populations.
Market Segmentation by Indication
Indication-based segmentation in 2023 revealed diverse preferences. While Hypercholesterolemia led in revenues in 2023, coronary artery disease demonstrated the highest CAGR during the forecast period of 2024 to 2032. Higher Triglycerides also played a significant role, highlighting the comprehensive approach of cholesterol-lowering drugs in addressing various cardiovascular risk factors.
Market Segmentation by Distribution Channel
Distribution channel segmentation in 2023 provided insights into industry preferences. Hospital Pharmacies led in revenue, reflecting the significant role of healthcare institutions in prescribing and dispensing cholesterol-lowering medications. Retail Pharmacies exhibited the highest CAGR during the forecast period of 2024 to 2032, showcasing the growing trend of community-based healthcare and accessibility. Online Pharmacies demonstrated steady growth, catering to the increasing demand for convenient medication procurement.
North America Remains the Global Leader
Geographically, the Cholesterol-lowering Drugs market displayed dynamic trends. North America led in terms of revenue in 2023, driven by the high prevalence of cardiovascular diseases and a robust healthcare infrastructure. However, the Asia-Pacific region exhibited the highest CAGR during the forecast period of 2024 to 2032, fuelled by the increasing awareness of cardiovascular health, rising disposable incomes, and a growing aging population.
Market Competition to Intensify during the Forecast Period
Top players in the Cholesterol-Lowering Drugs market employed diverse strategies to maintain their positions. Companies such as Pfizer, AstraZeneca, Amgen, Sanofi, GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., and AbbVie, Inc. showcased a strong focus on research and development, strategic partnerships, and global expansions. As of 2023, these players collectively dominated the market, with an expected continuation of their strategic initiatives during the forecast period from 2024 to 2032.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Cholesterol Lowering Drugs market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report
Micro and macro environment factors that are currently influencing the Cholesterol Lowering Drugs market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Drug Class
- Statins & Combination
- PCSK9 Inhibitors
- Bile Acid Sequestrants
- Fibrates
- Cholesterol
- Absorption Inhibitors
- Others
Indication
- Hypercholesterolemia
- Coronary Artery Disease
- Higher Triglycerides
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region Segment (2022-2032; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Key questions answered in this report
What are the key micro and macro environmental factors that are impacting the growth of Cholesterol Lowering Drugs market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2032.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Cholesterol Lowering Drugs market?
Which is the largest regional market for Cholesterol Lowering Drugs market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Cholesterol Lowering Drugs market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Cholesterol Lowering Drugs market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Cholesterol Lowering Drugs Market
- 2.2. Global Cholesterol Lowering Drugs Market, By Drug Class, 2023 (US$ Million)
- 2.3. Global Cholesterol Lowering Drugs Market, By Indication, 2023 (US$ Million)
- 2.4. Global Cholesterol Lowering Drugs Market, By Distribution Channel, 2023 (US$ Million)
- 2.5. Global Cholesterol Lowering Drugs Market, By Geography, 2023 (US$ Million)
- 2.6. Attractive Investment Proposition by Geography, 2023
3. Cholesterol Lowering Drugs Market: Competitive Analysis
- 3.1. Market Positioning of Key Cholesterol Lowering Drugs Market Vendors
- 3.2. Strategies Adopted by Cholesterol Lowering Drugs Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2023 Versus 2032
4. Cholesterol Lowering Drugs Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Cholesterol Lowering Drugs Market Value, 2022 - 2032, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
- 4.6. Porter's Five Force Model
- 4.6.1. Supplier Power
- 4.6.2. Buyer Power
- 4.6.3. Threat Of Substitutes
- 4.6.4. Threat Of New Entrants
- 4.6.5. Competitive Rivalry
- 4.7. PESTEL Analysis
- 4.7.1. Political Landscape
- 4.7.2. Economic Landscape
- 4.7.3. Technology Landscape
- 4.7.4. Legal Landscape
- 4.7.5. Social Landscape
5. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2023 Versus 2032
- 5.3. Market Segmentation
- 5.3.1. Statins & Combination
- 5.3.2. PCSK9 Inhibitors
- 5.3.3. Bile Acid Sequestrants
- 5.3.4. Fibrates
- 5.3.5. Cholesterol
- 5.3.6. Absorption Inhibitors
- 5.3.7. Others
6. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2023 Versus 2032
- 6.3. Market Segmentation
- 6.3.1. Hypercholesterolemia
- 6.3.2. Coronary Artery Disease
- 6.3.3. Higher Triglycerides
7. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 7.1. Market Overview
- 7.2. Growth & Revenue Analysis: 2023 Versus 2032
- 7.3. Market Segmentation
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail Pharmacies
- 7.3.3. Online Pharmacies
8. North America Cholesterol Lowering Drugs Market, 2022-2032, USD (Million)
- 8.1. Market Overview
- 8.2. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 8.3. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 8.4. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.5.Cholesterol Lowering Drugs Market: By Region, 2022-2032, USD (Million)
- 8.5.1.North America
- 8.5.1.1. U.S.
- 8.5.1.1.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 8.5.1.1.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 8.5.1.1.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.5.1.2. Canada
- 8.5.1.2.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 8.5.1.2.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 8.5.1.2.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.5.1.3. Rest of North America
- 8.5.1.3.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 8.5.1.3.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 8.5.1.3.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.5.1.1. U.S.
- 8.5.1.North America
9. UK and European Union Cholesterol Lowering Drugs Market, 2022-2032, USD (Million)
- 9.1. Market Overview
- 9.2. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 9.3. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 9.4. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.5.Cholesterol Lowering Drugs Market: By Region, 2022-2032, USD (Million)
- 9.5.1.UK and European Union
- 9.5.1.1. UK
- 9.5.1.1.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 9.5.1.1.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 9.5.1.1.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.5.1.2. Germany
- 9.5.1.2.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 9.5.1.2.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 9.5.1.2.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.5.1.3. Spain
- 9.5.1.3.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 9.5.1.3.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 9.5.1.3.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.5.1.4. Italy
- 9.5.1.4.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 9.5.1.4.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 9.5.1.4.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.5.1.5. France
- 9.5.1.5.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 9.5.1.5.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 9.5.1.5.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.5.1.6. Rest of Europe
- 9.5.1.6.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 9.5.1.6.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 9.5.1.6.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.5.1.1. UK
- 9.5.1.UK and European Union
10. Asia Pacific Cholesterol Lowering Drugs Market, 2022-2032, USD (Million)
- 10.1. Market Overview
- 10.2. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 10.3. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 10.4. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.5.Cholesterol Lowering Drugs Market: By Region, 2022-2032, USD (Million)
- 10.5.1.Asia Pacific
- 10.5.1.1. China
- 10.5.1.1.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 10.5.1.1.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 10.5.1.1.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.5.1.2. Japan
- 10.5.1.2.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 10.5.1.2.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 10.5.1.2.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.5.1.3. India
- 10.5.1.3.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 10.5.1.3.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 10.5.1.3.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.5.1.4. Australia
- 10.5.1.4.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 10.5.1.4.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 10.5.1.4.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.5.1.5. South Korea
- 10.5.1.5.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 10.5.1.5.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 10.5.1.5.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.5.1.6. Rest of Asia Pacific
- 10.5.1.6.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 10.5.1.6.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 10.5.1.6.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.5.1.1. China
- 10.5.1.Asia Pacific
11. Latin America Cholesterol Lowering Drugs Market, 2022-2032, USD (Million)
- 11.1. Market Overview
- 11.2. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 11.3. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 11.4. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.5.Cholesterol Lowering Drugs Market: By Region, 2022-2032, USD (Million)
- 11.5.1.Latin America
- 11.5.1.1. Brazil
- 11.5.1.1.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 11.5.1.1.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 11.5.1.1.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.5.1.2. Mexico
- 11.5.1.2.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 11.5.1.2.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 11.5.1.2.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.5.1.3. Rest of Latin America
- 11.5.1.3.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 11.5.1.3.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 11.5.1.3.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.5.1.1. Brazil
- 11.5.1.Latin America
12. Middle East and Africa Cholesterol Lowering Drugs Market, 2022-2032, USD (Million)
- 12.1. Market Overview
- 12.2. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 12.3. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 12.4. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 12.5.Cholesterol Lowering Drugs Market: By Region, 2022-2032, USD (Million)
- 12.5.1.Middle East and Africa
- 12.5.1.1. GCC
- 12.5.1.1.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 12.5.1.1.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 12.5.1.1.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 12.5.1.2. Africa
- 12.5.1.2.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 12.5.1.2.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 12.5.1.2.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 12.5.1.3. Rest of Middle East and Africa
- 12.5.1.3.1. Cholesterol Lowering Drugs Market: By Drug Class, 2022-2032, USD (Million)
- 12.5.1.3.2. Cholesterol Lowering Drugs Market: By Indication, 2022-2032, USD (Million)
- 12.5.1.3.3. Cholesterol Lowering Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 12.5.1.1. GCC
- 12.5.1.Middle East and Africa
13. Company Profile
- 13.1. Pfizer
- 13.1.1. Company Overview
- 13.1.2. Financial Performance
- 13.1.3. Product Portfolio
- 13.1.4. Strategic Initiatives
- 13.2. AstraZeneca
- 13.2.1. Company Overview
- 13.2.2. Financial Performance
- 13.2.3. Product Portfolio
- 13.2.4. Strategic Initiatives
- 13.3. Amgen
- 13.3.1. Company Overview
- 13.3.2. Financial Performance
- 13.3.3. Product Portfolio
- 13.3.4. Strategic Initiatives
- 13.4. Sanofi
- 13.4.1. Company Overview
- 13.4.2. Financial Performance
- 13.4.3. Product Portfolio
- 13.4.4. Strategic Initiatives
- 13.5. GlaxoSmithKline plc
- 13.5.1. Company Overview
- 13.5.2. Financial Performance
- 13.5.3. Product Portfolio
- 13.5.4. Strategic Initiatives
- 13.6. Novartis AG
- 13.6.1. Company Overview
- 13.6.2. Financial Performance
- 13.6.3. Product Portfolio
- 13.6.4. Strategic Initiatives
- 13.7. Merck & Co., Inc.
- 13.7.1. Company Overview
- 13.7.2. Financial Performance
- 13.7.3. Product Portfolio
- 13.7.4. Strategic Initiatives
- 13.8. Takeda Pharmaceutical Company Limited
- 13.8.1. Company Overview
- 13.8.2. Financial Performance
- 13.8.3. Product Portfolio
- 13.8.4. Strategic Initiatives
- 13.9. Sun Pharmaceutical Industries Ltd.
- 13.9.1. Company Overview
- 13.9.2. Financial Performance
- 13.9.3. Product Portfolio
- 13.9.4. Strategic Initiatives
- 13.10. AbbVie, Inc.
- 13.10.1. Company Overview
- 13.10.2. Financial Performance
- 13.10.3. Product Portfolio
- 13.10.4. Strategic Initiatives
- 13.11. Other Notable Players
- 13.11.1. Company Overview
- 13.11.2. Financial Performance
- 13.11.3. Product Portfolio
- 13.11.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 2 Global Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 3 Global Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 4 North America Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 5 North America Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 6 North America Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 7 U.S. Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 8 U.S. Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 9 U.S. Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 10 Canada Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 11 Canada Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 12 Canada Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 13 Rest of North America Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 14 Rest of North America Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 15 Rest of North America Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 16 UK and European Union Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 17 UK and European Union Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 18 UK and European Union Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 19 UK Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 20 UK Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 21 UK Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 22 Germany Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 23 Germany Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 24 Germany Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 25 Spain Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 26 Spain Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 27 Spain Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 28 Italy Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 29 Italy Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 30 Italy Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 31 France Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 32 France Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 33 France Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 34 Rest of Europe Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 35 Rest of Europe Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 36 Rest of Europe Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 37 Asia Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 38 Asia Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 39 Asia Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 40 China Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 41 China Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 42 China Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 43 Japan Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 44 Japan Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 45 Japan Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 46 India Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 47 India Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 48 India Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 49 Australia Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 50 Australia Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 51 Australia Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 52 South Korea Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 53 South Korea Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 54 South Korea Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 55 Latin America Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 56 Latin America Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 57 Latin America Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 58 Brazil Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 59 Brazil Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 60 Brazil Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 61 Mexico Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 62 Mexico Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 63 Mexico Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 64 Rest of Latin America Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 65 Rest of Latin America Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 66 Rest of Latin America Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 67 Middle East and Africa Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 68 Middle East and Africa Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 69 Middle East and Africa Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 70 GCC Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 71 GCC Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 72 GCC Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 73 Africa Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 74 Africa Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 75 Africa Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 76 Rest of Middle East and Africa Cholesterol Lowering Drugs Market By Drug Class, 2022-2032, USD (Million)
- TABLE 77 Rest of Middle East and Africa Cholesterol Lowering Drugs Market By Indication, 2022-2032, USD (Million)
- TABLE 78 Rest of Middle East and Africa Cholesterol Lowering Drugs Market By Distribution Channel, 2022-2032, USD (Million)
List of Figures
- FIG. 1 Global Cholesterol Lowering Drugs Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Cholesterol Lowering Drugs Market: Quality Assurance
- FIG. 5 Global Cholesterol Lowering Drugs Market, By Drug Class, 2023
- FIG. 6 Global Cholesterol Lowering Drugs Market, By Indication, 2023
- FIG. 7 Global Cholesterol Lowering Drugs Market, By Distribution Channel, 2023
- FIG. 8 Global Cholesterol Lowering Drugs Market, By Geography, 2023
- FIG. 9 Market Geographical Opportunity Matrix - Global Cholesterol Lowering Drugs Market, 2023
FIG. 10Market Positioning of Key Cholesterol Lowering Drugs Market Players, 2023
FIG. 11Global Cholesterol Lowering Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032
- FIG. 12 Global Cholesterol Lowering Drugs Market, By Drug Class, 2023 Vs 2032, %
- FIG. 13 Global Cholesterol Lowering Drugs Market, By Indication, 2023 Vs 2032, %
- FIG. 14 Global Cholesterol Lowering Drugs Market, By Distribution Channel, 2023 Vs 2032, %
- FIG. 15 U.S. Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 16 Canada Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 17 Rest of North America Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 18 UK Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 19 Germany Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 20 Spain Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 21 Italy Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 22 France Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 23 Rest of Europe Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 24 China Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 25 Japan Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 26 India Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 27 Australia Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 28 South Korea Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 29 Rest of Asia Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 30 Brazil Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 31 Mexico Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 32 Rest of Latin America Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 33 GCC Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 34 Africa Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
- FIG. 35 Rest of Middle East and Africa Cholesterol Lowering Drugs Market (US$ Million), 2022 - 2032
